PT  - JOURNAL ARTICLE
AU  - Camisa, Charles
AU  - Schacht, Gretchen E.
AU  - O’Dorisio, Thomas M.
AU  - Maceyko, Ronald F.
TI  - Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201–995 (Sandostatin)
DP  - 1990 Jan 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 57--81
VI  - 57
IP  - 1
4099  - http://www.ccjm.org/content/57/1/57.2.short
4100  - http://www.ccjm.org/content/57/1/57.2.full
SO  - Cleve Clin J Med1990 Jan 01; 57
AB  - Nine patients with psoriasis vulgaris were treated for 12 weeks with somatostatin analog, octreotide acetate (SMS 201-995) 50 or 100 μg by subcutaneous injection every 12 hours. The purposes of the study were to determine: (1) levels of insulin, glucose, glucagon, pancreatic polypeptide (PP), and SMS 201-995 after a subcutaneous injection of SMS 201-995 and ingestion of a standardized meal; (2) nocturnal (0200 h) thyroid stimulating hormone (TSH) levels before, during, and after treatment; and (3) the pharmacokinetics of SMS 201-995. Insulin peaks at 30 minutes were blunted from 65.8 ± 11.0 μU/mL without treatment to 26.7 ± 8.6 μU/mL and 7.7 ± 2.0 μU/mL after the 50- and 100-μg doses, respectively. Glucagon levels remained constant during the meal and were not affected by the 50-μ, g dose. Mean glucose levels were significantly elevated during insulin suppression. PP was also rapidly suppressed by SMS 201-995 and remained so for 4 hours after the injection. Nocturnal TSH was blunted after 12 weeks of treatment (P ≤ .05). T4 and T3 resin uptake showed no depression, and patients remained clinically euthyroid. The plasma peak of SMS 210-995 occurred 30 minutes postinjection and half-life was longer than 2 hours. After chronic administration of SMS 201-995, insulin was suppressed with resultant mild carbohydrate intolerance that persisted throughout the treatment course.